A share price of Soleno Therapeutics Inc [SLNO] is currently trading at $45.53, up 20.16%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SLNO shares have gain 21.28% over the last week, with a monthly amount glided 6.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on February 05, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $93. Previously, Stifel started tracking the stock with Buy rating on January 23, 2024, and set its price target to $63. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 29, 2020. Craig Hallum initiated its recommendation with a Buy and recommended $8 as its price target on January 10, 2020. Oppenheimer started tracking with a Outperform rating for this stock on December 23, 2019, and assigned it a price target of $10. In a note dated February 13, 2018, Maxim Group reiterated an Buy rating on this stock and revised its target price from $8 to $4.
Soleno Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.16 and $53.82. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $45.53 at the most recent close of the market.
Analyzing the SLNO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.8 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.20 points at the first support level, and at 38.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.33, and for the 2nd resistance point, it is at 57.13.
Soleno Therapeutics Inc [SLNO] reported earnings per share of -$0.33 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.27/share, meaning a difference of -$0.06 and a surprise factor of -22.20%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.95 per share as compared to estimates of -$0.58 per share, a difference of -$0.37 representing a surprise of -63.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Soleno Therapeutics Inc [NASDAQ:SLNO] is 14.89. Also, the Quick Ratio is 14.89, while the Cash Ratio stands at 14.75.
Transactions by insiders
Recent insider trading involved Anish Bhatnagar, CHIEF EXECUTIVE OFFICER, that happened on Apr 01 ’24 when 18980.0 shares were sold. CHIEF FINANCIAL OFFICER, Mackaness James H completed a deal on Apr 01 ’24 to sell 5175.0 shares. Meanwhile, Yen Kristen sold 2218.0 shares on Apr 01 ’24.
